According to a study led by University of Michigan researchers, fewer than one-third of hospitals had immediate availability of all-trans retinoic acid (ATRA), which is initiated early in the treatment of acute promyelocytic leukemia to prevent major bleeding, clotting, and potential death.
Molecular markers in blood at birth are linked to later development of acute lymphoblastic leukemia, the most common cancer type that affects children, according to a study published in Molecular Cancer.
